Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.55 |
| ▸ | PPARA | Q07869 | 12/20 | 0.55 |
| ▸ | KLK7 | P49862 | 2/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24115494 | 0.87 | PPARG (0.47) | PPARGPPARAKLK7SLC1A3SLC1A2 | |
| SCHEMBL9554385 | 0.84 | SRR (0.57) | PPARGPPARAKLK7ACE | |
| SCHEMBL22767763 | 0.81 | PPARG (0.57) | PPARGPPARASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL22767860 | 0.80 | PPARG (0.56) | PPARGPPARASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL22767761 | 0.79 | PPARG (0.49) | PPARGPPARASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL15446174 | 0.79 | SRR (0.68) | PPARGPPARASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL15446199 | 0.79 | SRR (0.68) | PPARGPPARASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL22767931 | 0.77 | PPARG (0.53) | PPARGPPARASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL26357303 | 0.77 | SLC1A3 (0.62) | PPARGPPARASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL22767894 | 0.76 | PPARG (0.59) | PPARGPPARAPPARDACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | HIROSHIMA UNIVERSITY (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | HIROSHIMA UNIVERSITY (JP) | 2024-01-25 | — | — | US | disclosed |
| EP-4248997-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR COVID-19 | Hiroshima University (JP) | 2023-09-27 | — | — | EP | disclosed |
| US-11203565-B2 | Ester compound and PIN1 inhibitor, inflammatory disease therapeutic, and colon cancer therapeutic in which said ester compound is used | HIROSHIMA UNIVERSITY (JP) | 2021-12-21 | — | — | US | disclosed |
| US-11071738-B2 | Therapeutic agent for fatty liver diseases and therapeutic agent for adiposity | HIROSHIMA UNIVERSITY (JP) | 2021-07-27 | — | — | US | disclosed |
| US-20200383989-A1 | Therapeutic Agent for Fatty Liver Diseases and Therapeutic Agent for Adiposity | HIROSHIMA UNIVERSITY (JP) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383989-A1 | Therapeutic Agent for Fatty Liver Diseases and Therapeutic Agent for Adiposity | FABP1, LIPC, SLC10A1 | PPARG 29/4885PPARA 18/4885KLK7 1508/4885 |
| US-11203565-B2 | Ester compound and PIN1 inhibitor, inflammatory disease therapeutic, and colon cancer therapeutic in which said ester compound is used | PIN1, APC, GSKIP | PPARG 184/4885PPARA 262/4885KLK7 3561/4885 |
| US-11071738-B2 | Therapeutic agent for fatty liver diseases and therapeutic agent for adiposity | FABP1, LIPC, SLC10A1 | PPARG 29/4885PPARA 18/4885KLK7 1508/4885 |
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | PIN1, ACE2, ACE | PPARG 1621/4885PPARA 1337/4885KLK7 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.